Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. Biochemical aspects.
Seventy-five outpatients with major depressive disorder (RDC) were randomly referred to treatment with a dominant 5-HT reuptake blocker (zimeldine, 100 mg b.i.d.) or a dominant NA reuptake blocker (maprotiline 75 mg b.i.d.). Pretreatment biochemical, pharmacodynamic and pharmacokinetic variables were studied and related to the treatment outcome with the two drugs. Female responders to the dominant 5-HT reuptake blocker were characterized by low pretreatment accumulation of 14C-5-HT in rat synaptosomes, when incubated in patient plasma. Among zimeldine responders there was a relationship between antidepressive effect and steady-state concentrations of zimeldine and norzimeldine. These findings support the hypothesis of a subgroup of depression characterized by serotonin disturbance.
D000818:Animals; D000873:Anthracenes / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use*; D009638:Norepinephrine / Q000097:blood*; D051381:Rats; D012701:Serotonin / Q000097:blood*; D012737:Sex Factors; D013574:Synaptosomes / Q000378:metabolism; D015031:Zimeldine / Q000627:therapeutic use*
D000873:Anthracenes; D008376:Maprotiline; D012701:Serotonin; D015031:Zimeldine; D009638:Norepinephrine